Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | XmAb808 |
Trade Name | |
Synonyms | XmAb-808|XmAb 808 |
Drug Descriptions |
XmAb808 is a bispecific antibody that targets CD276 (B7-H3) on tumor cells and CD28 expressed on T-lymphocytes, which potentially leads to enhanced antitumor immune response (Journal for ImmunoTherapy of Cancer 2023;11). |
DrugClasses | CD276 Antibody 16 |
CAS Registry Number | NA |
NCIT ID | C192709 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Pembrolizumab + XmAb808 | Pembrolizumab XmAb808 | 0 | 1 |
XmAb808 | XmAb808 | 0 | 0 |